Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

“…Baseline patient demographics and disease characteristics of the palmoplantar cohort were generally similar to those of the intent-to treat population in the primary analyses, although there appeared to be slightly higher proportions of male patients and those with severe disease. 14,15,19 The fairly high prevalence of palmoplantar involvement here differs sharply from reports indicating that it is seen in only a small subset of patients (5%-18%) who have psoriasis plaques on other areas of the body. 5,8,9 Important differences in patient selection criteria across some of these earlier studies and the current studies likely play a role in the differing prevalence and clinical characteristics of the palmoplantar psoriasis cases described.…”